'Intended-Use' Rule Delayed Indefinitely By US FDA
Executive Summary
A controversial change that could have broadened the definition of "intended use" to include almost anything discussed in manufacturer communications has been delayed indefinitely as FDA reopens the comment period.
You may also be interested in...
FDA Yields To Pressure, Delays ‘Intended Use’ Rule
The agency has granted a petition from trade groups to delay controversial revisions to its definition of “intended use” for at least one year, and is also gathering comments to guide possible further revisions.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Implant
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.